Galactosaminoglucuronoglycan sulphate in the treatment of osteoarthritis: Clinical efficacy and tolerance of oral and intra-articular administrations

International Journal of Clinical Pharmacology Research

Volumn 18, Issue 1, 1998, Pages 39-50

  Coaccioli, S ^a   Allegra, A ^b   Pennacchi, M ^b   Mattioli, C ^b   Ponteggia, F ^c   Brunelli, A ^b   Patucchi, E ^b   Puxeddu, A ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b S MARIA HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSAMINOGLUCURONOGLYCAN SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERANCE; DYSPHAGIA; EPIGASTRIC PAIN; FEMALE; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; RASH; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; COHORT STUDIES; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS; PAIN;

EID: 0031712734     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Kelsey J.L. "Epidemiology of muscoloskeletal disorders" New York, Oxford University Press, 1982, 78-82pp.
2. Peyron J.G. Osteoarthritis: the epidemiologic viewpoint Clin. Orthop., 213, 13 19, 1986.
3. Holbrook TL et al. "The frequency of occurrence, impact and cost of musculoskeletal conditions in the United States". Chicago, Am Acad Orthop Surg., 1984, pp. 1 180
4. Mankin H.J. The reaction of articular cartilage to injury and osteoarthritis. N. Engl. J Med., 291, 1285-1292 and 1335-1340. 1974.
5. Howell D S., Pita J.C., Woessner J.F. Jr. Biochemical changes in cartilage relevant to the cause and management of osteoarthritis. Rheumatology, 7, 29-45 1982.
6. Sokoloff L. Endemic forms of osteoarthritis. Clin. Rheum. Dis., 11, 187 202, 1985.
7. Mankin H.J., Brandt K.D., Shulman L.E. Workshop on etiopathogenesis of osteoarthritis: proceedings and recommendations J Rheumatol., 13, 1130-1160, 1986.
8. Moskowitz R.W. Introduction. In: Moskowitz R.W., Howell D.S., Goldberg V.M., Mankin H.J., eds "Osteoarthritis: diagnosis and treatment". Philadelphia. WB Saunders, pp 1-6, 1984.
9. Carrabba M., Colombo B., Chevallard M. Osteoartrosi. In: Carcassi U., ed "Trattato di Reumatologia" Soc. Ed. Universo, Roma, 1993, pp 1473-1538.
10. Pipitone V.R. Chondroprotection with chondroitin sulfate. Drugs Exptl. Clin. Res., 17, 3-7, 1991.
11. Maroudas A Biophysical chemistry of cartilagincus tissue with special reference to solute and fluid transport Bio-heology, 12, 233-238, 1975.
12. Comper W.D., Laurent T.C. Physiological function of connective tissue polysaccharides. Physiol. Rev., 58, 255 315, 1978
13. Coaccioli S., Puxeddu A. Le basi patogenetiche della malattia osteoartrosica. Seconde giornate reumatologiche dei Naharti, Terni, 9 11/5/1996. Abstract book, 1996, pp. 52-57.
14. Sledge C.B. Biology of the joint. In: Kelley W.N., Harris E.D., Ruddy S., Sledge C.B. "Textbook of rheumatology" W.B. Saunders Co., Philadelphia, 1993.
15. Brandt K.D., Mankin H.J. Pathogenesis of osteoarthritis. In: Kelley W.N., Harris E.D., Ruddy S., Sledge C.B. eds. Textbook of rheumatology". W.B. Saunders Co., Philadelphia, 1993, p. 1355-1364.
16. Hook M. Cell surface glycosaminoglycans. Ann. Rev. Biochem., 53, 847-869, 1984.
17. 4-labeled proteoglycans. Hoppe-Seyler's Z. Physiol, Chem., 356, 943-952, 1975.
18. Baici A, et al. Inhibition of human elastase from polymorphonuclear leucocytes by glycosaminoglycan polysulfate (Arteparon). Biochem. Pharmacol., 29, 1723-1727, 1980.
19. Lindahl U., Hook M. Glycosaminoglycans and their binding to biological macromolecules. Ann. Rev, Biochem., 47, 385-417, 1978
20. Baici A., Bradamante P, Interaction between human leukocyte elastase and chondroitin sulfate, Chem. Biol. Interact, 51, 1-11, 1984.
21. Di Pasquale G. Proteoglycan- and collagen-degrading enzyme from human interleukin-1-stimulated chondrocytes from several species: proteoglycanase and collagenase inhibitors as potentially new disease-modifying antiarthritic agents Proc Soc Exp. Biol. Med., 183, 262-267, 1986.
22. Cook T.D.V., Bennet E.L. Ohno O. Identification of immunoglobulins and complement component in articular collagenous tissues of patients with idiopathic osteoarthrosis. In: Nuki G., ed, The aetiopathogenesis of osteoarthrosis". Pitman Medical, London, 1980.
23. Raepple E, Hill H,U., Loos M. Mode of interaction of different polyanions with the first (C1), the second (C2) and the fourth (C4) components of complement Immunochemistry, 13, 251-255, 1976.
24. Paroli E., Antonili L., Biffoni M, A pharmacological approach to glycosaminoglycans. Drugs Exp Clin. Res., 17, 9-19, 1991.
25. Serni U., Mannoni A. Chondrocyte physiopathology and drug efficacy. Drugs Exp. Clin. Res. 17, 75-79, 1991.
26. Chistolini A., Mandelli F. Valutazione dei parametri coagulativi del soggetti sottoposti a terapia con galactosamino-glucuronoglicano. Farmaci Terapia, 6, 17-19, 1989.
27. Matera M., Scalia S. Anticoagulant activity of galactosaminoglucuronoglycan: a pharmacological study Drugs Exp. Clin. Res., 17, 65-73, 1991.
28. Soldani G., Romagnoli J. Experimental and clinical pharmacology of glycosaminoglycans (GAGGs). Drugs Exp. Clin. Res., 17, 81-85, 1991.
29. Fioravanti A. et al. Clinical efficacy and tolerance of galactosaminoglucuronoglycan sulfate in the treatment of osteoarthritis. Drugs Exp. Clin. Res., 17, 41-44, 1991.
30. D'Agnolo B. Valutazione degli effetti collaterali e della efficacia nel sintomo del dolore (in pazienti artrosici) del galactosaminoglucoronoglicano solfato. Clin. Eur., 2, 275-279, 1986.
31. Soliano A. Terapia con galattosaminoglucuronoglicano solfato, Clin. Eur., 2, 281-285, 1986.
32. Gusso M.I., Pavolini B., Ciampalani L Efficacia e tollerabilita del galattosaminoglucuronoglicano solfato nel trattamento dell'osteoartrosi. Farmaci Terapia, 7, 169-174, 1990.
33. Oliviero U, et al. Effects of the treatment with Matrix on elderly people with chronic articular degeneration. Drugs Exp. Clin. Res., 17, 45-51, 1991.
34. Galanti A.F. et al. Efficacy and tolerance of galactosaminoglucuronoglycan sulphate (Matrix) administered for 11 months in osteoarthritis of the knee. 4th Interscience World Confernece on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Geneva, April 15-18, 1991.
35. Rovetta G. Galactosaminoglucuronoglycan sulfate (Matrix) in therapy of tibiofemular osteoarthritis of the knee Drugs Exp. Clin. Res. 17, 53-57, 1991.
36. Spadaro A, et al. Valutazione laboratoristica a breve termine della tollerabilita del galattosaminoglucuronoglicano solfato (GAGGS) nella terapia dell'osteoartrosi. Ann. Rheumatol., 17, 55-59, 1988.
37. Megale F, et al. Efficacia e tollerabilita del galattosaminoglucuronoglicano solfato net trattamento dell'artrosi delle mani. XXVII Congresso Nazionale della Societa Italians di Reumatologia, Roma, 3-Nov 1989.
38. Savenano G., Lionetti P. Nostre considerazioni sull'applicazione del galattosaminoglucuronoglicano solfato come potenziamento della rieducazione motoria dell'osteoartrosi. Clin. Eur., Sept-Oct 5-10, 1985.
39. Vignon E., Conrozier T. Oral condroitin sulfate in the treatment of hip osteoarthritis (HOA). XII European Congress of Rheumatology Budapest, June 30-July 6, 1991.
40. Blotman F., Lolau G. Clinical trial with condroitin sulfate in gonarthrosis. XII European Congress of Rheumatology, Budapest, June 30-July 6, 1991.
41. Wang F.C et al. Long-term clinical trial with condroitin sulfate in osteoarthritis of the hand and its in vitro effects on the differentiated human chondrocytes. XII European Congress of Rheumatology, Budapest, June 30-July 6, 1991.
42. Frick E. Studio sull'efficacia e la tollerabilita del galattosaminoglucuronoglicano solfato. Ricerca clinica controllata vs placebo in pazienti affetti da condropatie femorc-patellari. XI Seminario di Studi Rheumatologici. Ancona, 4-6/5/1990.
43. L'Hirondel L. Valutazione dell'efficacia del galattosaminoglucuronoglicano solfato nette gonartrosi. Studio clinico controllato a doppia cecita. XI Seminario di Studi Reumalologici, Ancona, 4-6/5/1990.
44. Monforte P., Rovetta G., Bianchi G. Long termoral galactosaminoglucuronoglycan sulfate (GGGs) in erosive osteoarthritis patients. 4th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators, Geneva, April 15-18, 1991.
45. Pipitone V, et al. A multicentric triple-blind study to evaluate galactosaminoglucuronoglycan sulfate versus placebo in patients with femorotibial gonarthritis. Curr. Ther. Res., 52, 608-638, 1992.
46. Coaccioli S, et al. Chondroprotection: a chance or the reality in the therapy to osteoarthritis? Eur. Soc. for Osteoarthrology, 20th Symposium, Bari, Italy 29-9/1 10 1994, Abstract book, p. 96.
47. Patucchi E, et al. Terapia condroproptettiva per via orale in pazienti affetti da osteoartrosi. Seconde giornate reumatologiche dei Naharti. Terni, 9-11/5/1996. Abstract book, p. 194.
48. Brunelli A, et al. Terapia con galattosaminoglucuronoglicano solfatc per via intra-articolare nell's osteoartrosi di ginocchio. SEconde giorna:e reumatologiche dei Nahart. Terni, 9 11/5/1996. Abstract book p. 195.
49. Coaccioli S, et al. La terapia condropiotettiva nell'osteoartrosi: attualita e prospettive. Seconde giornate reumatologiche dei Naharti Terni, 9 11/5/1996. Abstract book, p. 193